Skip to main content
OpenTrials
Completed

NCT Number: NCT02969447

Management of Third-stage of Labor After Second Trimester Medical Pregnancy Termination

Prospective randomized trail which compare 2 regimens for third-stage management after second trimester medical pregnancy termination : 10UI intra venous oxytocin or no additional medication after fetal expulsion. Primary outcome was the incidence of placental retention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Retained Placenta Female Urogenital Diseases and Pregnancy Complications Placenta Diseases Placenta, Retained Pregnancy Complications Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

CHU de Bordeaux

Bordeaux, 33076, France

About this study

Complication of third stage of labor in second trimester medical pregnancy termination is not well studied. Accord to publications, the placental retention rate is 30 to 40% in these situations. Placental retention may be associated with increased blood loss, increased requirement for blood transfusion anesthetic and operative complications, and infectious morbidity. The high incidence of retained placenta is an area of clinical concern. Publications reveal a wide variation in practices but there are only few studies about third stage of labor in second trimester medical pregnancy termination. The study is a prospective randomized trial. Two third stage management strategies are compared: 10 units of intra venous oxytocin (group 1) and no additional medication (group 2) after fetal expulsion. It concerns pregnancies between 14 and 28 weeks gestation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years old and older
  • medical pregnancy termination between 14 and 28 weeks gestation
  • informed consent obtained

Exclusion criteria

  • less than 18 years old
  • refusal to consent
  • in utero fetal death

Treatment and study plan

Administration of 10 units of intra venous oxytocin after fetal expulsion

Drug

Primary outcomes

  1. Incidence of placental retention

    Time frame: Up to 30 minutes after fetal expulsion

Secondary outcomes

  1. Incidence of partial placental retention

    Time frame: Up to 1 hour after fetal expulsion

  2. Incidence of digital exploration

    Time frame: Up to 1 hour after fetal expulsion

  3. Incidence of blunt curettage

    Time frame: Up to 1 hour after fetal expulsion

  4. Incidence of post-partum hemorrhage

    Time frame: Up to 1 hour after fetal expulsion

  5. Blood loss

    Time frame: Up to 1 hour after fetal expulsion

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Effect of Intra-venous Oxytocin Injection After Fetal Expulsion in Management of Third-stage of Labor After Second Trimester Medical Pregnancy Termination

Acronym: ANDDROID

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Nov 21, 2016
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.